NuVasive
NuVasive raises $200M Convertible Note at $3.5B valuation
Quick Facts
NuVasive: Convertible Note Funding Round
NuVasive has successfully raised $200M in Convertible Note funding, reaching a valuation of $3.5B.
Company Overview
Minimally disruptive surgical products for spine
Funding Details
The Convertible Note round was led by TPG Capital, with participation from Goldman Sachs.
Company Information
- Headquarters: 7475 Lusk Boulevard, San Diego, CA 92121
- Founded: 1997
- Employees: 2800+
- Category: MedTech
Investment
NuVasive plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- TPG Capital: Verified investor in Convertible Note
- Goldman Sachs: Verified investor in Convertible Note
Key Investors
About the Author
Related Company Reports
NeuroLink Brain Raises $580M Series D to Transform Healthcare
NeuroLink Brain secures $580M in Series D funding at $8.2B valuation to complete fda approval process, scale manufacturing for clinical deployment, and expand treatment applications.
MedTech Revolution Secures $890M Series D to Lead MedTech Innovation
MedTech Revolution raises $890M in Series D funding at $13.7B valuation to complete clinical trials for 5 medical devices, scale robotic surgery systems, and expand to asian markets.
ForSight Robotics raises $125M Series B at $700M valuation
ForSight Robotics raises $125M in Series B at $700M valuation. Ophthalmic surgical robots...